Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 2
2020 7
2021 3
2022 7
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Kelley RK, et al. Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4. Lancet Oncol. 2022. PMID: 35798016 Free article. Clinical Trial.
Treatment-related grade 5 events occurred in six (1%) patients in the combination treatment group (encephalopathy, hepatic failure, drug-induced liver injury, oesophageal varices haemorrhage, multiple organ dysfunction syndrome, and tumour lysis syndro …
Treatment-related grade 5 events occurred in six (1%) patients in the combination treatment group (encephalopathy, hepatic failure, drug …
Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes.
Endo Y, Winarski KL, Sajib MS, Ju A, Wu WJ. Endo Y, et al. Int J Mol Sci. 2023 Jul 20;24(14):11694. doi: 10.3390/ijms241411694. Int J Mol Sci. 2023. PMID: 37511454 Free PMC article.
It is still not clear whether, targeting PD-L1 on hepatocytes, the atezolizumab may cause damage to liver cells contributing to hepatotoxicity. ...This study provides the molecular basis of the atezolizumab-induced hepatotoxicity and opens a new avenue …
It is still not clear whether, targeting PD-L1 on hepatocytes, the atezolizumab may cause damage to liver cells contributing t …
Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective.
Karamchandani DM, Chetty R. Karamchandani DM, et al. J Clin Pathol. 2018 Aug;71(8):665-671. doi: 10.1136/jclinpath-2018-205143. Epub 2018 Apr 27. J Clin Pathol. 2018. PMID: 29703758 Review.
However, a flip side of these novel drugs is immune-related adverse events (irAEs), secondary to immune-mediated process due to disrupted self-tolerance. The irAEs in the gastrointestinal (GI) tract/liver may result in diarrhoea, colitis or hepatitis. An accurate diagnosis …
However, a flip side of these novel drugs is immune-related adverse events (irAEs), secondary to immune-mediated process due to disrupted se …
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study.
Joerg V, Scheiner B, D Alessio A, Fulgenzi CAM, Schönlein M, Kocheise L, Lohse AW, Huber S, Wege H, Kaseb A, Wang Y, Mathew A, Kuang A, Muzaffar M, Abugabal YI, Chamseddine S, Phen S, Cheon J, Lee PC, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang YH, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal AG, Chon HJ, Pinato DJ, Schulze K, von Felden J. Joerg V, et al. Hepatol Commun. 2023 Oct 27;7(11):e0302. doi: 10.1097/HC9.0000000000000302. eCollection 2023 Nov 1. Hepatol Commun. 2023. PMID: 37889520 Free PMC article.
BACKGROUND: Since the introduction of the combination treatment of anti-programmed death-ligand 1 antibody atezolizumab and anti-VEGF antibody bevacizumab (AB), median overall survival in HCC has drastically improved. ...
BACKGROUND: Since the introduction of the combination treatment of anti-programmed death-ligand 1 antibody atezolizumab and anti-VEGF …
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.
Alden SL, Lim M, Kao C, Shu D, Singal AG, Noonan A, Griffith P, Baretti M, Ho WJ, Kamel I, Yarchoan M, Hsiehchen D. Alden SL, et al. Cancer Res Commun. 2023 Jul 20;3(7):1312-1317. doi: 10.1158/2767-9764.CRC-23-0072. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37484200 Free PMC article.
Of the 32 patients who met our inclusion criteria, prior anti-PD-(L)1 regimens included atezolizumab plus bevacizumab (50%, n = 16), other anti-VEGF plus anti-PD-(L)1 combinations (31%, n = 10), and anti-PD-(L)1 monotherapy (19%, n = 6). ...
Of the 32 patients who met our inclusion criteria, prior anti-PD-(L)1 regimens included atezolizumab plus bevacizumab (50%, n = 16), …
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
Vitale G, Lamberti G, Comito F, Di Nunno V, Massari F, Morelli MC, Ardizzoni A, Gelsomino F. Vitale G, et al. Expert Opin Biol Ther. 2020 Sep;20(9):1047-1059. doi: 10.1080/14712598.2020.1762562. Epub 2020 May 19. Expert Opin Biol Ther. 2020. PMID: 32425081 Review.
AREAS COVERED: We revised data from phase II/III clinical trials and real-world retrospective analyses on liver-related adverse events induced by anti-PD-1 (nivolumab/pembrolizumab) and anti-PD-L1 (atezolizumab) in advanced cancer populations (melanoma, NSCLC …
AREAS COVERED: We revised data from phase II/III clinical trials and real-world retrospective analyses on liver-related adverse event …
Anti programmed death-ligand 1 antibody-related cholangitis without bile duct dilation or stenosis.
Azami T, Takano Y, Noda J, Yamawaki M, Yoshida E, Niiya F, Maruoka N, Ogawa T, Ichikawa W, Nagahama M. Azami T, et al. Clin J Gastroenterol. 2022 Aug;15(4):818-821. doi: 10.1007/s12328-022-01651-3. Epub 2022 Jun 21. Clin J Gastroenterol. 2022. PMID: 35729450
Cholangitis has been reported as an immune-related adverse event, although it rarely occurs. Here we report a case of cholangitis due to atezolizumab in a 77-year-old woman who had been treated with atezolizumab and nab-paclitaxel for breast cancer and lung metastas …
Cholangitis has been reported as an immune-related adverse event, although it rarely occurs. Here we report a case of cholangitis due to …
Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapy.
Uojima H, Chuma M, Hidaka H, Tsuda T, Kobayashi S, Hattori N, Ogushi K, Arase Y, Take A, Sakaguchi Y, Tomoko A, Nishigori S, Wanatanbe T, Numata K, Morimoto M, Kagawa T, Kako M, Kusano C. Uojima H, et al. Eur J Gastroenterol Hepatol. 2023 Aug 1;35(8):865-873. doi: 10.1097/MEG.0000000000002581. Epub 2023 Jun 6. Eur J Gastroenterol Hepatol. 2023. PMID: 37395239
OBJECTIVE: To investigate the association between body composition and prognosis in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab. METHODS: This cohort study analysed 119 patients who received atezolizumab plus bevacizuma …
OBJECTIVE: To investigate the association between body composition and prognosis in patients with advanced hepatocellular carcinoma treated …
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L. Yau T, et al. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):310-322. doi: 10.1016/S2468-1253(23)00454-5. Epub 2024 Feb 13. Lancet Gastroenterol Hepatol. 2024. PMID: 38364832 Clinical Trial.
In the initial analysis, cabozantinib plus atezolizumab significantly prolonged progression-free survival versus sorafenib. ...Treatment-related deaths occurred in six (1%) patients in the combination treatment group (encephalopathy, hepatic failure, drug-induced …
In the initial analysis, cabozantinib plus atezolizumab significantly prolonged progression-free survival versus sorafenib. ...Treatm …
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.
Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H. Onoyama T, et al. World J Gastroenterol. 2020 Jan 21;26(3):353-365. doi: 10.3748/wjg.v26.i3.353. World J Gastroenterol. 2020. PMID: 31988594 Free PMC article.
Abdominal pain or discomfort (35.5%, 11/31) was the most frequent symptom. Blood serum tests identified liver dysfunction with a notable increase in biliary tract enzymes relative to hepatic enzymes, and a normal level of serum immunoglobulin G4. ...
Abdominal pain or discomfort (35.5%, 11/31) was the most frequent symptom. Blood serum tests identified liver dysfunction with a nota …
25 results